Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARA American Renal Associates	$11.52	$11.50	$5.57 ▼ $11.98	$397.94M	1.11	106,940 shs	9,831 shs
EWTX Edgewise Therapeutics	$13.17 +0.8%	$14.76	$10.60 ▼ $38.12	$1.37B	0.28	1.21 million shs	1.26 million shs
GRAL GRAIL	$48.39 -2.0%	$39.25	$12.33 ▼ $63.99	$1.78B	N/A	1.21 million shs	5.79 million shs
SDGR Schrodinger	$20.61 +0.6%	$23.19	$16.60 ▼ $28.47	$1.50B	1.63	908,927 shs	1.68 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARA American Renal Associates	0.00%	0.00%	0.00%	0.00%	0.00%
EWTX Edgewise Therapeutics	+0.84%	-7.90%	-5.86%	-43.40%	-24.66%
GRAL GRAIL	-2.00%	+6.05%	+17.77%	+79.69%	+4,838,999,900.00%
SDGR Schrodinger	+0.59%	+0.73%	-4.23%	+3.26%	+10.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARA American Renal Associates	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	3.4327 of 5 stars	4.4	3.0	0.0	0.0	2.0	3.3	0.0
GRAL GRAIL	0.5552 of 5 stars	1.1	1.0	0.0	0.0	2.3	0.8	1.3
SDGR Schrodinger	2.9229 of 5 stars	3.5	2.0	0.0	0.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARA American Renal Associates	0.00	N/A	N/A	N/A
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$39.78	202.03% Upside
GRAL GRAIL	2.25	Hold	$31.50	-34.90% Downside
SDGR Schrodinger	3.00	Buy	$32.80	59.15% Upside

Current Analyst Ratings Breakdown

Latest ARA, GRAL, EWTX, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00
5/14/2025	GRAL GRAIL	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $43.00
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/21/2025	GRAL GRAIL	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
4/16/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $32.00
4/3/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $52.00
4/2/2025	EWTX Edgewise Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $51.00
4/2/2025	EWTX Edgewise Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$50.00 ➝ $14.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARA American Renal Associates	$822.52M	0.48	$1.69 per share	6.80	$2.59 per share	4.45
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.84 per share	N/A
GRAL GRAIL	$125.60M	13.86	$28.30 per share	1.71	$74.50 per share	0.65
SDGR Schrodinger	$207.54M	7.29	N/A	N/A	$5.78 per share	3.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARA American Renal Associates	-$13.79M	$0.26	N/A	N/A	N/A	-2.04%	-3.56%	-0.24%	N/A
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.95%	-29.45%	8/6/2025 (Estimated)
GRAL GRAIL	-$2.03B	-$60.99	N/A	N/A	N/A	-1,464.53%	-17.99%	-15.02%	8/12/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)

Latest ARA, GRAL, EWTX, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	GRAL GRAIL	-$4.03	-$3.10	+$0.93	-$3.10	$35.80 million	$31.84 million
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARA American Renal Associates	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARA American Renal Associates	7.54	1.05	1.02
EWTX Edgewise Therapeutics	N/A	20.99	20.99
GRAL GRAIL	N/A	9.70	9.71
SDGR Schrodinger	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARA American Renal Associates	78.42%
EWTX Edgewise Therapeutics	N/A
GRAL GRAIL	N/A
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
ARA American Renal Associates	9.50%
EWTX Edgewise Therapeutics	23.20%
GRAL GRAIL	1.85%
SDGR Schrodinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARA American Renal Associates	4,977	34.54 million	N/A	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	80.79 million	Optionable
GRAL GRAIL	1,360	35.97 million	35.31 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable

ARA, GRAL, EWTX, and SDGR Headlines

Recent News About These Companies

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 27 at 11:28 AM | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 23, 2025 | globenewswire.com

17,493 Shares in Schrodinger, Inc. (NASDAQ:SDGR) Bought by Palumbo Wealth Management LLC

June 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 22, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 18, 2025 | globenewswire.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 17, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 16, 2025 | accessnewswire.comA

GAMMA Investing LLC Acquires 117,796 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

June 14, 2025 | marketbeat.com

SchrÃ¶dinger: Assessing The Signal And The Noise In The Phase 1 Results

June 13, 2025 | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 13, 2025 | accessnewswire.comA

Stanley Laman Group Ltd. Acquires 27,511 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

June 13, 2025 | marketbeat.com

Schrödinger slides after early-stage trial data for cancer therapy

June 12, 2025 | msn.com

Schrödinger (NASDAQ:SDGR) Stock Price Down 10.6% - Time to Sell?

June 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 12, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 11, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 10, 2025 | globenewswire.com

Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Buy" from Analysts

June 10, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 9, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 7, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 6, 2025 | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

June 6, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Ignore the Noise—Samsara Stock Is Still a Strong Buy
By Sam Quirke | June 12, 2025
View Ignore the Noise—Samsara Stock Is Still a Strong Buy
Will Warner Bros. Discovery’s Split Produce Double the Upside?
By Jeffrey Neal Johnson | June 11, 2025
View Will Warner Bros. Discovery’s Split Produce Double the Upside?
Joby's Saudi MoU: Strong Initial Reaction Meets Market Dynamics
By Jeffrey Neal Johnson | June 4, 2025
View Joby's Saudi MoU: Strong Initial Reaction Meets Market Dynamics
JPMorgan Chase: The Financial Fortress Built for Today's Investor
By Jeffrey Neal Johnson | June 23, 2025
View JPMorgan Chase: The Financial Fortress Built for Today's Investor

ARA, GRAL, EWTX, and SDGR Company Descriptions

American Renal Associates NYSE:ARA

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Edgewise Therapeutics NASDAQ:EWTX

$13.17 +0.11 (+0.84%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$12.95 -0.22 (-1.67%)

As of 06/27/2025 06:43 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

GRAIL NASDAQ:GRAL

$48.39 -0.99 (-2.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$47.94 -0.45 (-0.92%)

As of 06/27/2025 06:18 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Schrodinger NASDAQ:SDGR

$20.61 +0.12 (+0.59%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$20.64 +0.03 (+0.15%)

As of 06/27/2025 07:56 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time